Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
113,177,462
-
Number of holders
-
418
-
Total 13F shares, excl. options
-
82,930,091
-
Shares change
-
+3,332,402
-
Total reported value, excl. options
-
$5,250,281,341
-
Value change
-
+$233,179,536
-
Put/Call ratio
-
59%
-
Number of buys
-
266
-
Number of sells
-
-155
-
Price
-
$63.31
Significant Holders of Viking Therapeutics, Inc. - COMMON STOCK (VKTX) as of Q3 2024
535 filings reported holding VKTX - Viking Therapeutics, Inc. - COMMON STOCK as of Q3 2024.
Viking Therapeutics, Inc. - COMMON STOCK (VKTX) has 418 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 82,930,091 shares
of 113,177,462 outstanding shares and own 73% of the company stock.
Largest 10 shareholders include FMR LLC (16,619,430 shares), VANGUARD GROUP INC (10,167,614 shares), BlackRock, Inc. (5,380,323 shares), STATE STREET CORP (4,674,067 shares), JPMORGAN CHASE & CO (2,116,438 shares), MORGAN STANLEY (1,874,845 shares), GEODE CAPITAL MANAGEMENT, LLC (1,863,667 shares), PERCEPTIVE ADVISORS LLC (1,699,987 shares), CITADEL ADVISORS LLC (1,472,676 shares), and Pictet Asset Management Holding SA (1,361,510 shares).
This table shows the top 418 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.